Fapon Biopharma

What Fapon Biopharma does

Fapon Biopharma is a clinical-stage biotechnology company founded in 2015 and headquartered in Dongguan, China, with a secondary R&D center in Shanghai opened in 2022. It is a wholly owned subsidiary of Fapon Group, a diversified life sciences conglomerate, and develops therapeutic antibodies and fusion proteins targeting cancers and autoimmune diseases. The company's pipeline includes FP008 (anti-PD-1 x IL-10M fusion protein, currently in Phase I for solid tumors refractory to anti-PD-1 therapy), FP002 (humanized anti-CD47 monoclonal antibody with FDA IND approval), and preclinical candidates FP012, FPE024, FPE021, FP010, FP011, FPX004, and FPE022 spanning oncology, autoimmune disease, and inflammatory bowel disease indications. It also pursues an in vivo CAR-T program (MTX001) in partnership with sister company MOTE Therapeutics.

The company's technical foundation rests on four proprietary platforms: the FILTEN IL-10M Fusion Protein Platform, which overcomes the short half-life and hematotoxicity of wild-type IL-10; a Bi/Tri-TCE Platform using VHH nanobodies with human-cynomolgus cross-reactivity that enables preclinical safety validation in NHP models; the PROTiNb platform for targeted protein degradation of intracellular targets using mRNA-encoded VHH-E3 fusion proteins delivered via targeted LNPs; and the FIND Mammalian Cell Display antibody discovery platform. The CD3-VHH with cross-reactive binding is highlighted as enabling superior preclinical translation and smaller molecular weight for better solid tumor penetration.

Fapon Biopharma operates a B2B licensing and co-development business model. The company does not commercialize products directly; instead it pursues global partnerships with pharmaceutical and biotech companies through industry conference presence (BIO, AACR, European Life Sciences CEO Forum), scientific publications, and dedicated BD outreach channels for Americas/Europe and Asia-Pacific. Revenue streams, when they materialize, are expected to flow from upfront licensing payments, development and regulatory milestones, co-development cost-sharing, and royalties on net sales of approved therapeutics commercialized by partners. To date, the company is pre-revenue with no products marketed and operates without disclosed external venture or private equity funding.

Name

Fapon Biopharma

Legal name

Guangdong Fapon Biopharma Inc.

Website

https://en.faponbiopharma.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Fapon Biopharma is a clinical-stage Chinese biotech developing therapeutic antibodies and fusion proteins for cancer and autoimmune diseases through proprietary platforms, generating revenue via global licensing and co-development partnerships with pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Biopharmaceutical R&D

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Therapeutic antibodies development
• Fusion protein biologics
• Oncology drug discovery
• Autoimmune disease therapeutics
• Biologics licensing partnerships

Headquarters

HQ city

Dongguang

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Licensing Revenue: The company seeks to out-license its proprietary technology platforms and pipeline candidates to pharmaceutical partners globally. Licensing deals would include upfront payments, development milestones, and royalties on net sales.
2. Co-development Partnerships: The company pursues co-development arrangements with pharmaceutical partners who can contribute resources and expertise to advance pipeline candidates through clinical development, sharing development costs and future profits.
3. Milestone Payments: Development and regulatory milestones from partners including IND filings, clinical trial phases, and approvals generate non-dilutive capital as programs advance.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Fapon Biopharma is a clinical-stage biopharmaceutical company that discovers and develops therapeutic antibodies and fusion proteins for cancers, autoimmune diseases, and other conditions with unmet medical needs. Its offerings include a pipeline of drug candidates (such as FP008, FP002, FP012, FPE024, FPE021, MTX001) and proprietary drug discovery and engineering platforms (FILTEN IL-10M fusion protein platform, Bi/Tri-TCE VHH T-cell engager platform, PROTiNb targeted protein degradation platform, and FIND mammalian cell display antibody discovery platform). The company provides end-to-end capabilities from target discovery through CMC and early clinical development, and commercializes its assets primarily through licensing and co-development partnerships with pharmaceutical companies.

Product overview

Fapon Biopharma is a clinical-stage biotech company developing a differentiated pipeline of therapeutic antibodies and fusion proteins, alongside multiple proprietary technology platforms. The portfolio includes clinical-stage candidates FP008 (anti-PD-1×IL-10M fusion protein, Phase I for solid tumors) and FP002 (anti-CD47 antibody, IND-approved), plus preclinical candidates including FP012 (TL1A×IL10MM for inflammatory diseases), FPE024 (tri-specific TCE for autoimmune diseases), FPE021 (CDH17 TCE for GI cancers), and MTX001 (in vivo CAR-T via MOTE partnership). Core technology platforms include: FILTEN (IL-10M Fusion Protein Platform), Bi/Tri-TCE Platform (VHH human-cynomolgus cross-binding), PROTiNb (Proteolysis Targeting intra-Nanobody), and FIND™ Mammalian Cell Display Platform. MOTE Therapeutics' mobilize™ tLNP platform supports in vivo gene delivery programs.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• FP008 demonstrated potent tumor suppression at low concentrations in orthotopic tumor models using Nalm-6 and NCI-H929 cell lines with different expression patterns
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• MOTE TherapeuticscoreStrategic or Co-development Partner · 22 June 2026Both companies are members of Fapon Group and jointly present their dual-targeting (CD19×BCMA), dual-platform (TCE + in vivo CAR-T) B-cell immunotherapy franchise at BIO 2026. Fapon Biopharma contributes its proprietary VHH human-cynomolgus cross-binding T-cell engager platform while MOTE contributes its mobilize™ targeted LNP delivery platform. Both companies actively pursue co-development and licensing partnerships for their integrated pipeline.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Elpiscience Biopharma: China-based clinical-stage biotech developing bispecific antibodies and next-gen immunotherapies for oncology. Directly comparable as a similarly-sized Chinese biotech pursuing novel multi-specific antibody formats against overlapping target space (PD-1, CD47, tumor-associated antigens).
• Innovent Biologics: China-headquartered biotech with multiple approved biologics (sintilimab, mazdutide) and a broad bispecific/ADC pipeline. Directly comparable as a Chinese clinical-to-commercial biologics company with PD-1, CD47, and TCE programs targeting similar oncology and autoimmune indications.
• Cullinan Oncology: US clinical-stage oncology biotech with bispecific T-cell engager programs (e.g., CLN-978, CLN-619). Comparable as a TCE-focused biotech with similar pipeline stage, modality focus, and BD-driven go-to-market strategy targeting oncology and autoimmune indications.
• Compass Therapeutics: US clinical-stage biotech developing bispecific antibodies (e.g., CTX009, CTX112) for oncology. Comparable as a similarly-sized clinical-stage biotech focused on novel bispecific platforms and global out-licensing strategies in overlapping oncology indications.
• RemeGen: China-based clinical-stage biotech developing novel biologics including disitamab vedotin (HER2 ADC) and bispecific antibodies. Directly comparable as a Chinese biologics developer pursuing global licensing deals and competing in similar oncology targets with proprietary antibody platforms.
• Harbour BioMed: China-and-Boston-based biotech with heavy emphasis on bispecific antibodies (e.g., batoclimab) and antibody discovery platforms (H2L2, HCAb). Directly comparable for its bispecific platform technology and licensing-driven model targeting similar autoimmune and oncology indications.
• Akeso (Akeso Inc.): China-based clinical-stage biotech with approved bispecifics (e.g., ivonescimab, cadonilimab) and a pipeline targeting PD-1, CD47, and autoimmune indications. Directly comparable as a Chinese biotech developing novel bispecific/multispecific antibodies for oncology and autoimmune diseases through partnership-driven commercialization.

Broad incumbents

• GenScript Biotech / GenScript ProBio: Major China-based life sciences conglomerate with biologics discovery, CDMO services (ProBio), and cell therapy operations. Comparable as a broader Chinese life sciences group operating in adjacent biologics development and manufacturing space, though with a CDMO rather than asset-ownership focus.
• Genmab: Established Danish biotech with industry-leading bispecific antibody platform (DuoBody) and multiple approved products (epcoritamab, talquetamab). Comparable as a leading bispecific antibody platform company with global licensing deals, representing the mature peer benchmark for Fapon's VHH TCE platform.
• WuXi Biologics: World's largest biologics CDMO with extensive China-based manufacturing footprint and internal pipeline. Comparable as a Chinese biologics powerhouse with both CRO/CDMO services and proprietary antibody development, providing competitive infrastructure for similar pipeline assets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/faponbiotech
• Facebookfacebook.com/Fapongroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fapon Biopharma